Live Breaking News & Updates on Hypertriglyceridemia

Stay updated with breaking news from Hypertriglyceridemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investigational drug plozasiran shows promise in reducing severe hypertriglyceridemia

In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the investigational drug plozasiran reduced triglyceride levels by an average of 74% after 24 weeks of use without causing any significant safety concerns, according to research presented at the American College of Cardiology's Annual Scientific Session. ....

Daniel Gaudet , Arrowhead Pharmaceuticals , University Of Montreal , American College Of Cardiology Annual Scientific Session , American College Of Cardiology , American College , Annual Scientific , Acute Pancreatitis ,

High dietary insulin index associated with increased risk of metabolic unhealthiness, research show

Study explored the association between dietary insulin index (DII) and dietary insulin load (DIL) with metabolic healthy (MH) status and the serum levels of brain-derived neurotrophic factor (BDNF) and adropin among the Iranian adult population. ....

Scientific Reportsstudy , Blood Pressure , Insulin Resistance , Metabolic Disorders ,

EMA Warns That Omega-3-Acid Ethyl Esters May Cause AF

Atrial fibrillation will now be included as a common side effect in the Summary of Product Characteristics for medicinal products containing omega-3-acid ethyl esters. ....

Pharmacovigilance Risk Assessment Committee , European Medicines Agency , Product Characteristics , Patient Safety , Atrial Fibrillation , F Atrial Fibrillation , United Kingdom Site Content , Adverse Effects , Side Effects , Ipid Management ,

Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis

1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with pegozafermin led to increased rates of NASH resolution. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a disease characterized by hepatic inflammation and excess fat accumulation with or without fibrosis of the liver. Pegozafermin ....

Minute Medicine Inc , Rating Level , Controlled Trial , Confidence Interval , Chronic Disease , Nonalcoholic Steatohepatitis Outcomes , Recombinant Fibroblast Growth Factor 21 Analog ,